M&A Deal Summary |
|
---|---|
Date | 2024-10-24 |
Target | ImmPACT Bio |
Sector | Life Science |
Buyer(s) | Lyell |
Deal Type | Add-on Acquisition |
Advisor(s) | Cooley (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2018 |
Sector | Life Science |
Employees | 224 |
Revenue | 85M USD (2022) |
Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. Lyell was founded in 2018 and is based in South San Francisco, California with facilities in Seattle and Bothell, Washington.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Add-on Acquisition) | 1 of 1 |
State (California) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2024) | 1 of 1 |